logo
Plus   Neg
Share
Email

AstraZeneca Announces Approval For Tagrisso In China - Quick Facts

AstraZeneca (AZN.L,AZN) said Tagrisso has received marketing authorisation in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer. The company said the approval from China's National Medical Products Administration followed the Priority Review Pathway and is based on results from the Phase III FLAURA trial.

Tagrisso was approved in China in 2017 and added to the National Reimbursement Drug List effective from January 2019 for the 2nd-line treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brick-and-mortar retailers reported mixed results as they head into the holiday season, as department store chain Kohl's Corp. (KSS) and Home Depot Inc.'s (HD) sales dropped, while discount retailer TJX Cos. (TJX) recorded strong sales growth. Shares of Home Depot slipped 5% after the home-improvement... The U.S. government has issued a new 90-day license extension that will allow U.S. companies to continue doing business with Chinese telecom giant Huawei Technologies Co. Ltd. This is the third 90-day license extension given by the U.S. to Huawei, the world's largest telecom equipment maker. The extension was given in order to minimize disruption for Huawei's customers. Chick-fil-A said it will no longer donate money to two Christian organizations that have been accused of anti-LGBTQ stances - the Fellowship of Christian Athletes and the Salvation Army. The two organizations have been criticized for their statements about same-sex marriage and homosexuality in the past. Chick-fil-A too faced a backlash after its CEO Dan Cathy said he opposed same-sex marriage.
Follow RTT
>